First Horizon Advisors’s Inovio Pharmaceuticals INO Stock Holding History

First Horizon Advisors’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-83	Closed	-$820	–	2493
2023 Q1	$820	Hold	83	–	–	﹤0.01%	2316
2022 Q4	$1.56K	Hold	83	–	–	﹤0.01%	2130
2022 Q3	$2K	Hold	83	–	–	﹤0.01%	2006
2022 Q2	$2K	Hold	83	–	–	﹤0.01%	2096
2022 Q1	$4K	Hold	83	–	–	﹤0.01%	1335
2021 Q4	$5K	Hold	83	–	–	﹤0.01%	1754
2021 Q3	$7K	Buy	+83	New	+$8.33K	﹤0.01%	1656
2014 Q1	–	Sell	-10	Closed	-$1K	–	1430
2013 Q4	$1K	Buy	+10	New	+$1K	﹤0.01%	1277

Other funds holding INO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

First Horizon Advisors's INO Position: Q2 2023 in Review

First Horizon Advisors sold out of Inovio Pharmaceuticals (INO) in Q2 2023, closing a stake of 83 shares — an estimated $820 sold.

First Horizon Advisors first reported a position in INO in Q4 2013 and held it in 8 quarters. The position peaked at $7K in Q3 2021. 133 funds tracked by Wall St. Rank hold INO as of Q2 2023.

First Horizon Advisors reported no remaining Inovio Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
First Horizon Advisors sold 83 Inovio Pharmaceuticals shares in Q2 2023, an estimated $820.
First Horizon Advisors first reported a position in Inovio Pharmaceuticals in Q4 2013 and held it in 8 quarters.
First Horizon Advisors's Inovio Pharmaceuticals position peaked at $7K in Q3 2021.
133 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2023.

Based on First Horizon Advisors's 13F filing for Q2 2023, filed 3 Aug 2023.